Oculis nets about $15.6 mln
Oculis, a Swiss developer of ophthalmic drugs, has raised CHF 15.5 million (about $15.6 million) in funding. Tekla Capital Management LLC led the round with participation from other investors that included Nan Fung Life Sciences.
4 January 2019•5 mins read
